Clinical Trial

A Trial to Assess the Pharmacokinetic Similarity Between CHS-1420 40 mg/0.4 mL and HUMIRA® (Adalimumab) 40 mg/0.4 mL in Healthy Chinese Adult Participants Under Fasting Conditions

Completed Phase 1
View on ClinicalTrials.gov →
Summary
A Single-Center, Randomized, Single-Blind, Single-Dose, Parallel-Group Trial to Assess the Pharmacokinetic Similarity Between CHS-1420 40 mg/0.4 mL and HUMIRA® (Adalimumab) 40 mg/0.4 mL in Healthy Chinese Adult Participants under Fasting Conditions
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-21; most recent amendment 2026-01-08.
Trial Details
NCT Number NCT07147257
Lead Sponsor Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
Conditions Healthy Participants
Enrollment 238 participants
Start Date 2025-02-12
Primary Completion 2025-05-06 (estimated)
Study Completion 2025-05-29 (estimated)
Updated on ClinicalTrials.gov 2026-01-28